Aptevo Therapeutics Inc. (APVO) stock
APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.59−0.07 (-10.00%)
Close on Nov 13, 2026Market cap $1.07MP/E –Yield –
Aptevo Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Aptevo Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$26.69M. For fiscal 2025 it was -$26.07M. The highest annual figure on record is -$20.26M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$26.07M | – |
| FY2024 | Dec 31, 2024 | -$24.25M | – |
| FY2023 | Dec 31, 2023 | -$28.31M | – |
| FY2022 | Dec 31, 2022 | -$27.74M | – |
| FY2021 | Dec 31, 2021 | -$20.26M | – |
| FY2020 | Dec 31, 2020 | -$26.09M | – |
| FY2019 | Dec 31, 2019 | -$38.73M | – |
| FY2018 | Dec 31, 2018 | -$49.28M | – |
| FY2017 | Dec 31, 2017 | -$50.82M | – |
| FY2016 | Dec 31, 2016 | -$135.41M | – |
| FY2015 | Dec 31, 2015 | -$58.19M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.41M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.80M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.92M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.56M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.18M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.42M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.93M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.27M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.44M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.03M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.58M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.52M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.56M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.29M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.46M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.42M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.59M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.48M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.95M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.50M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.17M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.40M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.91M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.32M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.86M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.99M | – |
| Q3 FY2018 | Sep 30, 2018 | -$11.53M | – |
| Q2 FY2018 | Jun 30, 2018 | -$11.84M | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.91M | – |
| Q4 FY2017 | Dec 31, 2017 | -$16.69M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.07M | – |
| Q2 FY2017 | Jun 30, 2017 | -$13.77M | – |
| Q1 FY2017 | Mar 31, 2017 | -$11.29M | – |
| Q4 FY2016 | Dec 31, 2016 | -$14.10M | – |
| Q3 FY2016 | Sep 30, 2016 | -$89.33M | – |
See a number that looks wrong?